Table 3 Post hoc comparison of the baseline demography and clinical features among the three PD clusters.

From: Biomarker characterization of clinical subtypes of Parkinson Disease

Post-hoc comparison of other variables

Cluster A

Cluster B

Cluster C

p value*

q value**

severe cluster

intermediate

mild cluster

n = 43

n = 98

n = 65

Sex: male

29 (67%)

56 (57%)

37 (57%)

0.46

0.4600

MCI

35 (81%)

63 (64%)

10 (15%)

<0.001

<0.0019

MoCA Score

23 (19–26)

25 (22–27)

28 (26–29)

<0.001

<0.0019

NMSS Total Score

26 (14–43)

11 (6–18)

16 (9–32)

<0.001

<0.0019

NMSSD1Score (cardiovascular)

0 (0–4)

0 (0–0)

0 (0–0)

0.003

0.0050

NMSSD2Score (sleep/fatigue)

4 (0–8)

0 (0–3)

1 (0–5)

<0.001

<0.0019

NMSSD3Score (mood/apathy)

1 (0–5)

0 (0–0)

0 (0–2)

<0.001

<0.0019

NMSSD4Score (perceptual problems)

0 (0–0)

0 (0–0)

0 (0–0)

0.27

0.2893

NMSSD5Score (attention/memory)

1 (0–4)

0 (0–1)

0 (0–2)

0.027

0.0338

NMSSD6Score (gastrointestinal)

2 (0–7)

0 (0 - 2)

0 (0–3)

0.004

0.006

NMSSD7Score (urinary)

5 (4–12)

4 (0–5)

2 (0–5)

<0.001

<0.0019

NMSSD8Score (sexual function)

0 (0–2)

0 (0–0)

0 (0–0)

0.26

0.2893

NMSSD9Score (miscellaneous)

0 (0–3)

0 (0–3)

1 (0–4)

0.024

0.0327

LEDD

205.5 ± 103.5

211.3 ± 142.3

162.5 ± 147.8

0.089

0.1458

  1. Categorical variables reported as frequency (%); continuous variables reported as mean ± standard deviation or median and first and third quartile (where appropriate)
  2. *Chi-square or Fisher exact test (where appropriate) for categorical variables, One-way ANOVA or Kruskal Wallis test for continuous variables (depends on normality assumption)
  3. **False discovery rate (FDR) method was performed and q values were calculated to control for multiple testing and the threshold of q values was set as 0.1.
  4. MCI mild cognitive impairment, H&Y Modified Hoehn and Yahr (H&Y) staging scale, NMSS non-motor symptom scale, LEDD levodopa equivalent daily dose.
Back to article page